腾盛博药-B发布年度业绩，股东应占亏损2.23亿元 同比收窄56.19%

Core Viewpoint - Tengsheng Bo Pharmaceutical-B (02137) reported a significant increase in revenue for the fiscal year ending December 31, 2025, amounting to RMB 18.605 million, compared to zero revenue in the same period last year. The company also narrowed its net loss to RMB 222.3 million, a 56.19% improvement year-on-year, with a loss per share of RMB 0.31 [2]. Financial Performance - The company's revenue increased due to payments received under a licensing and technology transfer agreement with Health Yuan Group (600380) [2]. - The net loss for the year was RMB 222.3 million, which represents a 56.19% reduction compared to the previous year [2]. - Earnings per share were reported at a loss of RMB 0.31 [2].